634 results match your criteria Diabetes Therapy [Journal]


Correction to: Evaluating the User Performance and Experience with a Re-Engineered 4mm × 32G Pen Needle: A Randomized Trial with Similar Length/Gauge Needles.

Diabetes Ther 2019 Apr 17. Epub 2019 Apr 17.

BD (Becton, Dickinson and Company), Franklin Lakes, NJ, USA.

In the original publication, Figure 7 legend was incorrectly published as "A breakdown of preference for the comparator PN (black), no preference (grey), and preference for the investigational PN (white), in all groups combined, in all VAS questions". The correct legend is given below. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0623-5
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0623-5DOI Listing
April 2019
1 Read

Efficacy and Safety of Basal Analog Regimens in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Diabetes Ther 2019 Apr 6. Epub 2019 Apr 6.

Department of Endocrinology, Drum Tower Hospital Affiliated with Nanjing University Medical School, Nanjing, China.

Introduction: This study compared basal analog (BA: glargine U100/mL and detemir) and premix (PM: human, lispro and aspart biphasic) insulin regimens in terms of their efficacy and safety in type 2 diabetes mellitus patients.

Methods: Searches of MEDLINE, Embase, and CENTRAL identified primary randomized controlled trials (RCTs) ≥ 12 weeks in duration that compared BA or PM insulin regimens in adults with T2DM, with ≥ 30 patients per arm. A systematic literature review and a pairwise meta-analysis were performed using a random effects model adjusted for between-study variability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0606-6DOI Listing
April 2019
1 Read

A Survey of the FDA's Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use.

Diabetes Ther 2019 Apr 5. Epub 2019 Apr 5.

Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, People's Republic of China.

Introduction: We tested the possible association between sodium glucose cotransporter-2 inhibitor (SGLT-2i) use and urogenital tract infection (UTI) occurrences by assessing the publicly available US Food and Drug Administration Adverse Event Reporting System (FAERS).

Methods: Disproportionality analysis and Bayesian analysis were used to mine FAERS for suspected UTI data for SGLT-2i use from the first quarter of 2004 to the second quarter of 2018.

Results: On the basis of 37,100 reports, 1628 reports (4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0611-9DOI Listing

Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial.

Diabetes Ther 2019 Apr 4. Epub 2019 Apr 4.

Eli Lilly Japan K.K., Kobe, Japan.

Introduction: Dulaglutide is a recombinant glucagon-like peptide-1 immunoglobulin G4 Fc fusion protein approved for treating patients with type 2 diabetes (T2D). The aim of this study was to assess postprandial data over 4 weeks for dulaglutide (0.75 mg) versus placebo after a standardized test meal in Japanese patients with T2D. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0605-7DOI Listing
April 2019
1 Read

Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials.

Diabetes Ther 2019 Apr 4. Epub 2019 Apr 4.

Scripps Whittier Diabetes Institute, Scripps Health, 10140 Campus Point Drive Suite 200, San Diego, CA, 92121, USA.

Introduction: Insulin dosing based on carbohydrate counting is the gold standard for improving glycaemic control in type 1 diabetes (T1D). This post hoc analysis aimed to explore the efficacy and safety of fast-acting insulin aspart (faster aspart) according to bolus dose adjustment method in people with T1D.

Methods: Post hoc analysis of two 26-week, treat-to-target, randomised trials investigating treatment with double-blind mealtime faster aspart, insulin aspart (IAsp), or open-label post-meal faster aspart (onset 1, n = 1143; onset 8, n = 1025). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0608-4DOI Listing
April 2019
1 Read

Combined Effects of Energy Intake and Physical Activity on Obesity in Japanese Patients with Type 2 Diabetes (JDDM 50): A Cross-Sectional Study.

Diabetes Ther 2019 Apr 3. Epub 2019 Apr 3.

Faculty of Medicine, Niigata University, Niigata, Japan.

Introduction: The combined effects of energy intake (EI) and physical activity (PA) on obesity have been poorly investigated. We have investigated the combined effects of EI and PA quantitatively in Japanese men and women with type 2 diabetes.

Methods: Data on 1395 patients with type 2 diabetes who attended 25 diabetes clinics located throughout Japan, obtained by questionnaire, were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0610-xDOI Listing

A Case Report of Fulminant Type 1 Diabetes Mellitus Caused by Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Iodine-Induced Thyrotoxicosis.

Diabetes Ther 2019 Apr 1. Epub 2019 Apr 1.

Department of Endocrinology, Key Laboratory of Endocrinology of National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

A 46-year-old woman presented with rash, fever, lymphadenopathy, eosinophilia and liver dysfunction. She had been treated with ornidazole for facial rosacea 2 months previously. Two weeks following presentation, she developed diabetic ketoacidosis with exhausted beta islets (2 h postprandial laboratory values: glucose 22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0607-5DOI Listing
April 2019
1 Read

Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan.

Diabetes Ther 2019 Mar 29. Epub 2019 Mar 29.

Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-Ku, Fukuoka, 810-8563, Japan.

Herein we describe four patients with acquired hemophilia A (AHA) caused by factor VIII (FVIII) inhibitor and histories of dipeptidyl peptidase-4 inhibitor (DPP4-I) treatment for diabetes mellitus (DM). Drug exposure can cause a breakdown of immune tolerance to FVIII associated with CD4 T cells, resulting in the induction of autoantibodies against FVIII. In patient 1 in the present series, FVIII inhibitor disappeared after DPP4-I treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0609-3DOI Listing
March 2019
1 Read

Laboratory Computer-Based Interventions for Better Adherence to Guidelines in the Diagnosis and Monitoring of Type 2 Diabetes.

Diabetes Ther 2019 Mar 28. Epub 2019 Mar 28.

Department of Radiology, University of Missouri, Columbia, MO, USA.

Introduction: The aim was to present two automated laboratory strategies designed to detect new cases of type 2 diabetes and prediabetes and improve their monitoring.

Methods: To improve diabetes diagnosis, we automatically registered the glycated hemoglobin (HbA1c) levels of every primary care patient between 25 and 46 years old in case of abnormal lipid testing when an HbA1c test had not been requested in the current order or during the previous year and when fasting glucose was > 100 mg/dl. We counted the number of detected cases of diabetes and prediabetes and calculated the cost per identified patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0600-zDOI Listing

Multiple Antihyperglycemic Drug Use is Associated with Undernutrition Among Older Adults with Type 2 Diabetes Mellitus: A Cross-Sectional Study.

Diabetes Ther 2019 Mar 28. Epub 2019 Mar 28.

Department of Internal Medicine, University of Health Sciences, Gulhane Faculty of Medicine, Ankara, Turkey.

Introduction: Undernutrition is prevalent in older age. Current management of type 2 diabetes mellitus (T2DM) requires modified diet patterns; however, older adults with diabetes may also be at the risk of undernutrition due to age, disease, and medication-related factors. Our objectives in this study were to examine the proportion and associations of undernutrition among community-dwelling older adults with T2DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0602-xDOI Listing

Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study.

Diabetes Ther 2019 Mar 27. Epub 2019 Mar 27.

University Hospital "Alexandrovska", Sofia, Bulgaria.

Introduction: This study aimed to demonstrate the beneficial effect of lixisenatide as add-on therapy to oral antidiabetics (OADs) in type 2 diabetes mellitus (T2DM) patients in routine clinical practice in Bulgaria.

Methods: This was a prospective, observational, multicentre study evaluating the real-life effectiveness and safety of 24-week treatment with lixisenatide in previously uncontrolled T2DM patients on combination therapy with metformin and sulfonylurea on highest tolerable doses.

Results: A total of 262 patients were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0603-9DOI Listing

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in "Real-World" Management of Type 2 Diabetes Mellitus: The G-FORCE Study.

Diabetes Ther 2019 Mar 27. Epub 2019 Mar 27.

Novartis Pharma nv-sa, Medialaan 40, 1800, Vilvoorde, Belgium.

Introduction: Randomized clinical trials showed that vildagliptin is well tolerated and leads to clinically meaningful decreases in glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) both in monotherapy and as add-on therapy in inadequately controlled type 2 diabetes mellitus (T2DM) patients. Nevertheless, there is an increased interest for real-life studies to confirm the clinical trial findings in the setting of a daily clinical practice. The aim of this study was to evaluate the effectiveness and tolerability of vildagliptin in a real-life clinical setting and to explore factors determining drug adherence and T2DM management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0601-yDOI Listing

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study.

Diabetes Ther 2019 Mar 25. Epub 2019 Mar 25.

Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Straße 173, 55216, Ingelheim am Rhein, Germany.

Introduction: Empagliflozin, a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, improves glycaemic control in patients with type 2 diabetes mellitus (T2DM) by inducing urinary glucose excretion. Combination therapy with empagliflozin and glucagon-like peptide-1 (GLP-1) receptor agonists had not previously been assessed, so we investigated the safety, tolerability and efficacy of empagliflozin as an add-on therapy to liraglutide, a GLP-1 receptor agonist.

Methods: This was a randomised, double-blind, parallel-group phase 4 trial of empagliflozin (10 mg or 25 mg) for 52 weeks as an add-on therapy to liraglutide (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0604-8DOI Listing

Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.

Diabetes Ther 2019 Mar 23. Epub 2019 Mar 23.

Jiangling County People's Hospital of Cardiology, Jingzhou, Hubei, People's Republic of China.

Introduction: With recent advances in interventional cardiology where percutaneous coronary intervention (PCI) has become the most preferred invasive strategy and with advances in adjunctive pharmacotherapy, several newer oral P2Y inhibitors have reached the market. In this analysis, we aimed to compare the cardiovascular outcomes and bleeding events which were associated with the use of cangrelor versus clopidogrel in patients with type 2 diabetes mellitus (T2DM) 48 h after PCI.

Methods: The electronic databases MEDLINE (PubMed), www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0593-7DOI Listing
March 2019
1 Read

Real-Life Management and Effectiveness of Insulin Pump with or Without Continuous Glucose Monitoring in Adults with Type 1 Diabetes.

Diabetes Ther 2019 Mar 21. Epub 2019 Mar 21.

Diabetes Unit, Endocrinology and Nutrition Department, Hospital Clínic, Barcelona, Spain.

Introduction: To describe and compare the routine use of continuous subcutaneous insulin infusion (CSII) in type 1 diabetes (T1D) patients with and without continuous glucose monitoring (CGM) in routine clinical practice and its relationship with glycemic outcomes.

Methods: Retrospective observational case-control study collecting routine use of CSII and CGM in T1D patients between January 2016 and December 2016. Patients with T1D using sensor augmented pump (SAP) were matched by sex and disease duration in a 1:3 ratio with those treated only with CSII. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0599-1DOI Listing

Downregulation of T-Cell Transcription Factors in Adult Latent Autoimmune Diabetes with High-Titer Glutamic Acid Decaroxylase Antibody.

Diabetes Ther 2019 Mar 20. Epub 2019 Mar 20.

Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Introduction: Latent autoimmune diabetes in adults (LADA) shows a heterogeneous clinical profile that is dependent on the glutamic acid decaroxylase antibody (GADA) titer. We speculated that LADA patients with a high or low GADA titer may have distinct T-lymphocyte subset profiles and distinct expression patterns of transcription factors involved in T-cell immunomodulation.

Methods: Patients with LADA (n = 40) and type 2 diabetes (T2DM; n = 14) were recruited to the study, and peripheral blood mononuclear cells were isolated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0594-6DOI Listing
March 2019
1 Read

Establishing Expert, Multi-Disciplinary, Peer-Reviewed Consensus to Lead a Paradigm Shift in Optimal Blood Glucose Management.

Diabetes Ther 2019 Mar 19. Epub 2019 Mar 19.

Triducive Ltd., Tunbridge Wells, UK.

Introduction: The National Health Service (NHS) in the UK appears unclear on how blood glucose monitoring (BGM) should be used to support diabetes patient care and empowerment, and local interpretation of NICE guidance on the availability of devices varies widely. An expert group of clinicians and commissioners considered BGM in terms of access, guidance, resources, data integration, patient education, and patient choice.

Methods: The group generated a series of questions on BGM into a 38-statement questionnaire using Delphi methodology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0598-2DOI Listing

Study Protocol for the Effects of Artificial Intelligence (AI)-Supported Automated Nutritional Intervention on Glycemic Control in Patients with Type 2 Diabetes Mellitus.

Diabetes Ther 2019 Mar 15. Epub 2019 Mar 15.

Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Introduction: Nutritional intervention is effective in improving glycemic control in patients with type 2 diabetes but requires large inputs of manpower. Recent improvements in photo analysis technology facilitated by artificial intelligence (AI) and remote communication technologies have enabled automated evaluations of nutrient intakes. AI- and mobile-supported nutritional intervention is expected to be an alternative approach to conventional in-person nutritional intervention, but with less human resources, although supporting evidence is not yet complete. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0595-5DOI Listing
March 2019
1 Read

Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus.

Diabetes Ther 2019 Mar 15. Epub 2019 Mar 15.

First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushyu, 807-8555, Japan.

Glucagon-like peptide-1 (GLP-1) receptor agonists improve postprandial glucose, lipid metabolism, and vascular endothelial function. However, little is known about the effect of hypoglycemia on vascular endothelial function in patients on GLP-1 receptor agonist therapy. The aim of the present study was to determine the effect of hypoglycemia on vascular endothelial function in patients with type 2 diabetes mellitus (T2DM) treated with exenatide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0596-4DOI Listing
March 2019
4 Reads

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis.

Diabetes Ther 2019 Mar 14. Epub 2019 Mar 14.

Nightingale Hospital, Kolkata, India.

Introduction: Although the positive effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on hospitalization for heart failure in type 2 diabetes (T2D) seem definite, some doubt exists about their effects on atherosclerotic cardiovascular disease (ASCVD). This study aims to shed light on this debatable issue.

Methods: An electronic database search (Cochrane Library, PubMed and Embase) was performed using two groups of terms ["sodium glucose cotransporter2 inhibitor", "dapagliflozin", "canagliflozin", "empagliflozin", "ertugliflozin"] AND ["major adverse cardiac events", "MACE", "cardiovascular death or hospitalization for heart failure", non-fatal myocardial infarction", "non-fatal stroke", "cardiovascular death", "hospitalization for heart failure"] and the cardiovascular outcome trials (CVOT) and pre-approval studies in phase 3 of all the SGLT2i analysed using comprehensive meta-analysis (CMA) software, version 3, Biostat Inc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0597-3DOI Listing
March 2019
3 Reads

Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes.

Diabetes Ther 2019 Apr 8;10(2):437-449. Epub 2019 Mar 8.

Sanofi Aventis, Chilly-Mazarin, France.

Treatment persistence (continuing to take medication for the prescribed period) and treatment adherence (complying with the prescription in terms of drug schedules and dosage) are both important when treating chronic diseases such as type 2 diabetes (T2D). They can be indicators of patient satisfaction with treatment. In T2D, the achievement of optimal outcomes requires both persistence with and adherence to prescribed therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0590-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437240PMC

Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment.

Diabetes Ther 2019 Apr 7;10(2):735-749. Epub 2019 Mar 7.

Patient-Centered Research, Evidera, Seattle, WA, USA.

Introduction: The incidence and prevalence of type 2 diabetes mellitus (T2D) are increasing in Japan, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat the disease. The objective of this study was to use a discrete choice experiment (DCE) to characterize patient preferences for clinical treatment features of two GLP-1 RAs-dulaglutide 0.75 mg and semaglutide 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0591-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437254PMC

Excessive Sodium Bicarbonate Infusion May Result in Osmotic Demyelination Syndrome During Treatment of Diabetic Ketoacidosis: A Case Report.

Diabetes Ther 2019 Apr 6;10(2):765-771. Epub 2019 Mar 6.

Division of Critical Care, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.

Introduction: We present a case wherein diabetic ketoacidosis (DKA) was treated with a large amount of sodium bicarbonate and potassium chloride, resulting in the development of osmotic demyelination syndrome (ODS).

Case Presentation: Our patient was a 29-year-old male with a history of post-surgical repair for ventricular septal defect. Upon arrival, the patient's Glasgow Coma Scale (GCS) score was E2M4V3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0592-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437239PMC
April 2019
2 Reads

The Association Between Trimester-Specific Weight Gain and Severe Preeclampsia/Adverse Perinatal Outcome in Gestational Diabetes Mellitus Complicated by Preeclampsia: A Retrospective Case Study.

Diabetes Ther 2019 Apr 5;10(2):725-734. Epub 2019 Mar 5.

Department of Obstetrics, Xiamen Maternal and Child Healthcare Hospital, Xiamen, 361003, Fujian, People's Republic of China.

Introduction: Gestational diabetes mellitus (GDM) and preeclampsia share many risk factors, e.g., gestational weight gain (GWG). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0589-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437224PMC
April 2019
1 Read

EADSG Guidelines: Insulin Storage and Optimisation of Injection Technique in Diabetes Management.

Diabetes Ther 2019 Apr 27;10(2):341-366. Epub 2019 Feb 27.

Department of Internal Medicine, Rwanda Military Hospital, Kigali, Rwanda.

To date, insulin therapy remains the cornerstone of diabetes management; but the art of injecting insulin is still poorly understood in many health facilities. To address this gap, the Forum for Injection Technique and Therapy Expert Recommendations (FITTER) published recommendations on injection technique after a workshop held in Rome, Italy in 2015. These recommendations are generally applicable to the majority of patients on insulin therapy, athough they do not explore alternative details that may be suitable for low- and middle-income countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0574-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437255PMC
April 2019
5 Reads

A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes.

Diabetes Ther 2019 Apr 27;10(2):683-696. Epub 2019 Feb 27.

School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Introduction: In both randomized controlled trials and real-world studies, liraglutide has demonstrated glycemic and body weight benefits in patients with type 2 diabetes. However, persistence with diabetes medication can be challenging. This study compared glycated hemoglobin (HbA) and other outcomes in patients with type 2 diabetes who continued treatment with liraglutide for over 12 months with those who discontinued treatment earlier, in a real-life setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0583-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437242PMC
April 2019
5 Reads

Higher Baseline Serum Irisin Decreases Risk for Body Mass Index Increment in Chinese Populations: A 3.2-Year Cohort Study.

Diabetes Ther 2019 Apr 27;10(2):713-723. Epub 2019 Feb 27.

Department of Endocrinology and Metabolism, Affiliated Hospital of Guizhou Medical University, No. 28, Guiyi Road, Guiyang, China.

Introduction: Irisin, a newly discovered myokine, exerts beneficial effects on energy metabolism. However, published results from studies examining the relationship between irisin concentration and obesity have been conflicting. The aim of our study was to investigate the association between serum irisin level and obese individuals with different body mass index (BMI) values and to explore the question of whether serum irisin can predict the risk of increases in the BMI. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0588-4
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0588-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437307PMC
April 2019
5 Reads

Evaluating the User Performance and Experience with a Re-Engineered 4 mm × 32G Pen Needle: A Randomized Trial with Similar Length/Gauge Needles.

Diabetes Ther 2019 Apr 27;10(2):697-712. Epub 2019 Feb 27.

BD (Becton, Dickinson and Company), Franklin Lakes, NJ, USA.

Introduction: Since insulin pens were first introduced in 1985, many advances have been made in pen needles (PNs). In this study we evaluated patient-reported outcomes of an investigational newly re-engineered 4 mm × 32G PN, the BD Nano™ 2nd Gen (also known by its "PRO" brand extension in many markets outside of the USA). In place of a conventional cylindrical posted hub, the investigational PN's hub is contoured with an expanded surface area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0585-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437253PMC
April 2019
2 Reads

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes.

Diabetes Ther 2019 Apr 20;10(2):649-662. Epub 2019 Feb 20.

Quantitative Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark.

Introduction: The aim of the present analysis was to characterise the absorption, distribution and elimination of semaglutide by means of population pharmacokinetic (PK) models using data from nine clinical pharmacology trials conducted in both healthy subjects and those with type 2 diabetes.

Methods: Data were obtained from trials with subcutaneous and intravenous administration of semaglutide that utilised frequent PK sampling and included a total of 353 subjects with 10,573 concentration values.

Results: Semaglutide PK properties across trials, drug product strengths and populations were well characterised by a two-compartment model with first-order absorption and elimination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0581-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437231PMC

C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.

Diabetes Ther 2019 Apr 20;10(2):673-681. Epub 2019 Feb 20.

Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Introduction: Despite the widespread use of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1ras) to improve glycemic regulation, with a low risk of hypoglycemia and weight reduction, their effectiveness varies among individuals. This study aimed to identify predictors of the efficacy of GLP-1ra on Hemoglobin A1c (HbA1c) in patients with insulin-independent diabetes.

Methods: In total, 58 patients with insulin-independent diabetes were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0586-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437227PMC

Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).

Diabetes Ther 2019 Apr 20;10(2):663-672. Epub 2019 Feb 20.

Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic.

Introduction: Despite the continuously growing number of therapeutic options for patients with type 2 diabetes mellitus (T2DM), a large percentage of these individuals fail to achieve their glycated hemoglobin (HbA1c) target. The aim of this study was to determine the change in metabolic control in insulin-naïve T2DM patients inadequately controlled with oral antidiabetic drugs (OADs) at 6 months after initiating basal insulin treatment as add-on to existing OADs.

Methods: This was a non-interventional prospective study conducted from June 2013 to December 2014 in 137 centers in the Czech Republic under routine clinical practice conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0584-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437250PMC
April 2019
1 Read

Quality of Life is Markedly Impaired by Rheumatological and Skin Manifestations in Patients with Type 1 Diabetes: A Questionnaire Survey.

Diabetes Ther 2019 Apr 19;10(2):635-647. Epub 2019 Feb 19.

Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.

Introduction: To estimate lifetime prevalence of diabetes-related upper limb and non-acquired skin manifestations in a representative type 1 diabetes (T1D) population and to identify associations between these conditions and quality of life.

Methods: A questionnaire on these complications and measures of quality of life (World Health Organization-Five Well-Being Index [WHO-5]), depression, and diabetes-specific burden (Problem Areas in Diabetes [PAID] scale) was sent to all T1D patients in a Danish clinic (N = 583).

Results: The response rate was 68. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0587-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437232PMC
April 2019
1 Read

Improvement in Quality of Care for Patients with Type 2 Diabetes in Hungary Between 2008 and 2016: Results from Two Population-Based Representative Surveys.

Diabetes Ther 2019 Apr 15;10(2):757-763. Epub 2019 Feb 15.

Department of Preventive Medicine, Faculty of Public Health, University of Debrecen, Debrecen, Hungary.

Introduction: Due to the increasing trends of recent decades, diabetes prevalence has reached a frequency of 1/11 adults worldwide. However, this disadvantageous trend has not been accompanied by worsened outcome indicators; better short-term (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0582-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437308PMC
April 2019
6 Reads

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study.

Diabetes Ther 2019 Apr 14;10(2):617-633. Epub 2019 Feb 14.

Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Introduction: The LIGHTNING study applied conventional and advanced analytic approaches to model, predict, and compare hypoglycemia rates of people with type 2 diabetes (T2DM) on insulin glargine 300 U/ml (Gla-300) with those on first-generation (insulin glargine 100 U/ml [Gla-100]; insulin detemir [IDet]) or second-generation (insulin degludec [IDeg]) basal-insulin (BI) analogs, utilizing a large real-world database.

Methods: Data were collected between 1 January 2007 and 31 March 2017 from the Optum Humedica US electronic health records [EHR] database. Patient-treatments, the period during which a patient used a specific BI, were analyzed for patients who switched from a prior BI or those who newly initiated BI therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0568-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437256PMC
April 2019
3 Reads

Predictive Modeling of Hypoglycemia Risk with Basal Insulin Use in Type 2 Diabetes: Use of Machine Learning in the LIGHTNING Study.

Diabetes Ther 2019 Apr 14;10(2):605-615. Epub 2019 Feb 14.

Sanofi, Bridgewater, NJ, USA.

Introduction: Hypoglycemia remains a global burden and a limiting factor in the glycemic management of people with diabetes using basal insulins or oral antihyperglycemic drugs. Hypoglycemia data gleaned from randomized controlled trials (RCTs) have limited generalizability, as the strict RCT methodology and inclusion criteria do not fully reflect the real-world clinical picture. Therefore, real-world evidence, gathered from sources including electronic health records (EHR), is increasingly recognized as an important adjunct to RCTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0567-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437245PMC
April 2019
1 Read

The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm.

Diabetes Ther 2019 Mar 13;10(Suppl 1):1-13. Epub 2019 Feb 13.

Diabetes Research Centre, University of Leicester, Leicester, UK.

There is currently a worldwide epidemic of type 2 diabetes (T2D) that is predicted to increase substantially in the next few years. With 80% of the global T2D population living in low to middle-income countries, there are issues with cost and of access to appropriate medicines. The objective of this symposium was to provide an overview of the efficacy and safety of glucose-lowering drugs, focussing in particular on sulfonylureas (SUs) in patients with T2D using data taken from both randomised controlled trials (RCTs) and real-world studies, the application of strategies to ensure optimal patient adherence and clinical outcomes, and the optimal use of SUs in terms of dose adjustment and agent choice to ensure the best clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0573-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408564PMC

Association of the Serum Total Cholesterol to Triglyceride Ratio with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes: A Community-Based Study.

Diabetes Ther 2019 Apr 13;10(2):597-604. Epub 2019 Feb 13.

Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.

Introduction: The relationship of total cholesterol (TC) or triglyceride (TG) to diabetic retinopathy (DR) has proven difficult to determine. In addition, there is no report of any study of the correlation between the TC/TG ratio and DR. This study was therefore undertaken to investigate the relationship between the TC/TG ratio and DR in Chinese adults with type 2 diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0579-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437234PMC
April 2019
1 Read

Use of Continuous Glucose Monitoring in People with Type 1 Diabetes: Perspectives of Two People with Diabetes and Physician Perspective.

Diabetes Ther 2019 Apr 8;10(2):333-340. Epub 2019 Feb 8.

Department of Diabetes and Endocrinology, Guy's and St Thomas NHS Foundation Trust, London, UK.

This article details perspectives from two individuals with type 1 diabetes (T1DM) who use continuous glucose monitoring (CGM) devices to improve their quality of life and self-management of diabetes. It provides a unique perspective of how CGM can make living with T1DM safer and easier, while improving the time spent in the target glucose range (time in range). The perspectives of these two individuals highlight both the immediate need for improved access and support for CGM as well as the need for an understanding of the benefits of using non-medically approved technologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0576-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437230PMC

Insights for Care: The Healthcare Utilisation and Cost Impact of Managing Type 2 Diabetes-Associated Microvascular Complications.

Diabetes Ther 2019 Apr 8;10(2):575-585. Epub 2019 Feb 8.

Heart of England NHS Foundation Trust, Birmingham, UK.

Introduction: The increasing prevalence of type 2 diabetes (T2DM) in the UK imposes a significant burden on the National Health Service (NHS). Despite the availability of effective treatments, the loss of glycaemic control over time results in significant comorbidities, including nephropathy, neuropathy and retinopathy. The cost of treating these microvascular complications has not been well documented, and this study aimed to provide an accurate assessment of the healthcare resource utilisation (HCRU) associated with managing T2DM and its complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0548-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437252PMC
April 2019
1 Read

Diagnostic Accuracy of Glycated Haemoglobin and Average Glucose Values in Type 2 Diabetes Mellitus Treated with Premixed Insulin.

Diabetes Ther 2019 Apr 8;10(2):587-596. Epub 2019 Feb 8.

Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital of the Ministry of the Inferior and Administration, Warsaw, Poland.

Introduction: Studies assessing the relationship between glycated haemoglobin (HbA1c) and average blood glucose (ABG) were conducted in small groups of patients on different treatments and may be biased for these reasons. The aim of the study was to assess the relationship between HbA1c and ABG in a large group of type 2 diabetes patients treated with premix insulin.

Methods: In 4257 patients treated with premixed insulin, the parallel point-of-care assessment of HbA1c and ABG from the preceding 90 days (ABG90), calculated automatically from all values measured by the glucometer, was performed twice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0570-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437248PMC
April 2019
3 Reads

Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan.

Diabetes Ther 2019 Apr 7;10(2):549-562. Epub 2019 Feb 7.

Astellas Pharma Inc., Tokyo, Japan.

Introduction: The aim of this study was to evaluate the characteristics of new users of sodium glucose co-transporter-2 inhibitors (SGLT2i) in comparison with those of new users of other oral antidiabetic drugs (OADs) using data retrieved from three administrative databases in Japan.

Methods: This study included adult patients from each database who started an OAD between 2014 and 2017. Outpatients who started SGLT2i therapy were included in the SGLT2i cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0577-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437244PMC
April 2019
1 Read

Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland.

Diabetes Ther 2019 Apr 7;10(2):563-574. Epub 2019 Feb 7.

Nurmijärvi Health Centre, Nurmijärvi, Finland.

Introduction: Although primarily utilized in type 1 diabetes, continuous subcutaneous insulin infusion (CSII) represents a useful treatment alternative for patients with type 2 diabetes who are unable to achieve good glycemic control despite optimization of multiple daily injections (MDI). The aim of the analysis reported here was to investigate the long-term cost-effectiveness of CSII versus MDI in type 2 diabetes patients with poor glycemic control in Finland.

Methods: The IQVIA CORE Diabetes Model was used to make long-term projections of the clinical and economic outcomes associated with CSII use in type 2 diabetes, based on clinical input data from the OpT2mise trial, which showed that CSII was associated with a 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0575-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437241PMC
April 2019
1 Read

Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review.

Diabetes Ther 2019 Apr 6;10(2):429-435. Epub 2019 Feb 6.

First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.

Diabetes mellitus (DM) is a major risk factor for ischemic stroke. Moreover, patients with DM suffer more severe strokes and have worse functional outcome following an acute stroke than patients without DM. In this context, data from animal studies and emerging evidence from clinical studies suggest that incretin-based antihyperglycemic agents might exert beneficial effects in patients with DM who suffer ischemic stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0580-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437305PMC
April 2019
1 Read

Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation Therapy for Type 2 Diabetes Mellitus: An Updated Meta-Analysis.

Diabetes Ther 2019 Apr 6;10(2):535-547. Epub 2019 Feb 6.

Department of Hemopathology, Puyang City Oilfield General Hospital, Puyang City, Henan, People's Republic of China.

Introduction: Studies of the effects of stem cell therapy on type 2 diabetes mellitus (T2DM) have not reached consistent results. Our meta-analysis aimed to systematically evaluate the efficacy of autologous bone marrow-derived stem cells (ABM-MNCs) on T2DM.

Methods: We systematically searched PubMed, EMBASE, Web of Science, and the Cochrane Library for studies published between 1980 and May 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0578-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437223PMC

Effect of Remote Glucose Monitoring Utilizing Computerized Insulin Dose Adjustment Algorithms: A Pilot Project.

Diabetes Ther 2019 Apr 5;10(2):523-533. Epub 2019 Feb 5.

Mellitus Health Inc., Los Angeles, CA, USA.

Introduction: Primary care physicians are often challenged to adjust insulin doses. To facilitate this process, we evaluated in a safety net clinic the work flow and glycemic effects of remote glucose monitoring utilizing Federal Drug Administration (FDA) cleared, Conformité Européenne (CE) registered software that contained computerized algorithms for insulin dose adjustments to help clinicians make dosing decisions for insulin-requiring patients.

Methods: Patients taking insulin for at least 6 months with HbA1 levels of at least 8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0565-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437238PMC
April 2019
1 Read

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians.

Diabetes Ther 2019 Apr 31;10(2):393-428. Epub 2019 Jan 31.

Dr Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India.

The current diabetes management strategies not only aim at controlling glycaemic parameters but also necessitate continuous medical care along with multifactorial risk reduction through a comprehensive management concept. The sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a group of evolving antidiabetic agents that have the potential to play a pivotal role in the comprehensive management of patients with diabetes due to their diverse beneficial effects. SGLT2i provide moderate glycaemic control, considerable body weight and blood pressure reduction, and thus have the ability to lower the risk of macrovascular and microvascular complications. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0562-1
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0562-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437257PMC
April 2019
8 Reads

Efficacy of Real-Time Continuous Glucose Monitoring to Improve Effects of a Prescriptive Lifestyle Intervention in Type 2 Diabetes: A Pilot Study.

Diabetes Ther 2019 Apr 31;10(2):509-522. Epub 2019 Jan 31.

Commonwealth Scientific and Industrial Research Organisation, Health and Biosecurity, Sydney, Australia.

Introduction: Optimising patient adherence to prescribed lifestyle interventions to achieve improved blood glucose control remains a challenge. Combined use of real-time continuous glucose monitoring systems (RT-CGM) may promote improved glycaemic control. This pilot study examines the effects of a prescriptive lifestyle modification programme when combined with RT-CGM on blood glucose control and cardiovascular disease risk markers. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0572-z
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0572-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437235PMC
April 2019
1 Read

Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.

Diabetes Ther 2019 Apr 31;10(2):493-508. Epub 2019 Jan 31.

Ossian Health Economics and Communications, Basel, Switzerland.

Introduction: Few patients with type 2 diabetes mellitus (T2DM) achieve recommended glycemic control targets in the Czech Republic. Novel therapies, such as fixed-ratio combinations of basal insulin plus glucagon-like peptide-1 receptor agonists, may contribute to better glycemic control. In the analysis presented here, the present analysis assessed the long-term cost-effectiveness of two fixed-ratio combinations, IDegLira (insulin degludec/liraglutide) and iGlarLixi (insulin glargine/lixisenatide), for the treatment of patients with T2DM inadequately controlled with basal insulin from a healthcare payer perspective in the Czech Republic. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-019-0569-7
Publisher Site
http://dx.doi.org/10.1007/s13300-019-0569-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437226PMC
April 2019
4 Reads

A Practical Guide to Delivering Nutritional Advice to People with Diabetes.

Authors:
Pamela A Dyson

Diabetes Ther 2019 Apr 31;10(2):367-374. Epub 2019 Jan 31.

Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.

Dietary advice is fundamental to the management of diabetes. Although ideally such advice should be delivered by a state-registered dietitian, it is more usually delivered by other health professionals. The primary focus for those with type 1 diabetes is carbohydrate counting and insulin adjustment and for the majority of people with type 2 diabetes, weight management is key. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-018-0556-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437251PMC
April 2019
2 Reads

Real-Time Sharing and Following of Continuous Glucose Monitoring Data in Youth.

Diabetes Ther 2019 Apr 30;10(2):751-755. Epub 2019 Jan 30.

Dexcom, Inc., San Diego, CA, USA.

Background: Those caring for children and adolescents with diabetes often use glucose concentration and trending information in management decisions. Some continuous glucose monitoring (CGM) systems offer real-time sharing and monitoring capabilities through mobile apps carried by the person with diabetes and the caregiver(s), respectively. Few large studies have explored real-world associations between sharing and following, CGM utilization, and glycemic outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0571-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437306PMC
April 2019
1 Read